VistaGen Reports Topline Results from PALISADE-1 Phase 3 Clinical Trial for PH94B financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Baird Downgrades VistaGen Therapeutics (VTGN) to Neutral streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
VistaGen Therapeutics (NASDAQ:VTGN – Get Rating) is set to announce its earnings results after the market closes on Thursday, June 23rd. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. VTGN stock opened at $0.99 on Monday. The stock has a market cap of $204.46 million, a PE ratio of […]